· Novartis receives priority review by US FDA and filing acceptance by EMA for Kymriah® to treat patients with relapsed or refractory follicular lymphoma. October 26, 2021. Media Release. Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz.